The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression. The grants include funding for four novel programs with the potential to treat a range of diseases, including Alzheimer’s, Huntington’s, and Parkinson’s.
Annual Gala Raised over $3.25 million for Alzheimer’s Treatments
Sixth Annual Great Ladies Luncheon & Fashion Show most successful in event's history
For the second year in a row, the Alzheimer’s Drug Discovery Foundation (ADDF) has been chosen as Official Charity Partner of the 2016 TCS New York City Marathon. The race will take place on Sunday, November 6, 2016.
Grants awarded in the first two months of 2016 support researchers in the U.S. and Middle East pursuing drug programs, prevention studies, and research to accelerate clinical trials.
The Alzheimer's Drug Discovery Foundation (ADDF) has joined the BIRAX Initiative, which recently issues its third call for proposals. BIRAX brings together British and Israeli scientists to tackle some of the world’s most challenging diseases including cardiovascular and liver disease, diabetes and Parkinson’s.
We are partnering with PsychoGenics Inc. to bring its services to our grantees working on preclinical Alzheimer’s drug discovery programs.
Funded Researchers are pursuing diverse targets to treat Alzheimer's Disease.
At the December joint meeting, the ADDF Boards of Governors and Overseers welcomed seven new members.
On Monday, November 9, Margaret and Daniel Loeb received The Charles Evans Award from the ADDF at our Sixth Annual Fall Symposium & Luncheon. Thanks to the generosity of our donors, the Symposium & Luncheon raised more than $1 million, the most in the event’s history.